6EQM
Crystal Structure of Human BACE-1 in Complex with CNP520
Summary for 6EQM
Entry DOI | 10.2210/pdb6eqm/pdb |
Descriptor | Beta-secretase 1, ~{N}-[6-[(3~{R},6~{R})-5-azanyl-3,6-dimethyl-6-(trifluoromethyl)-2~{H}-1,4-oxazin-3-yl]-5-fluoranyl-pyridin-2-yl]-3-chloranyl-5-(trifluoromethyl)pyridine-2-carboxamide (3 entities in total) |
Functional Keywords | structure-based drug design, alzheimer's disease, aspartic acid proteinase, hydrolase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 45291.13 |
Authors | Rondeau, J.-M.,Wirth, E. (deposition date: 2017-10-13, release date: 2018-09-19, Last modification date: 2024-05-01) |
Primary citation | Neumann, U.,Ufer, M.,Jacobson, L.H.,Rouzade-Dominguez, M.L.,Huledal, G.,Kolly, C.,Luond, R.M.,Machauer, R.,Veenstra, S.J.,Hurth, K.,Rueeger, H.,Tintelnot-Blomley, M.,Staufenbiel, M.,Shimshek, D.R.,Perrot, L.,Frieauff, W.,Dubost, V.,Schiller, H.,Vogg, B.,Beltz, K.,Avrameas, A.,Kretz, S.,Pezous, N.,Rondeau, J.M.,Beckmann, N.,Hartmann, A.,Vormfelde, S.,David, O.J.,Galli, B.,Ramos, R.,Graf, A.,Lopez Lopez, C. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Mol Med, 10:-, 2018 Cited by PubMed: 30224383DOI: 10.15252/emmm.201809316 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.35 Å) |
Structure validation
Download full validation report